Did you know?

The stock had previously closed at $10.40. Specifically, insider Konstantinos Xynos sold 7,313 shares of Replimune Group stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $10.92, for a total transaction of $79,857.96.The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ...Replimune story: Amylyx snatched the landmark approval for its ALS drug. Now its seeking cash to foot the launch bill - Endpoints News and other headlines for Replimune Group Please click here if you are not redirected within a few seconds.PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA. REPL - Replimune Group Inc - Stock screener for ...8 Des 2022 ... ... Replimune's asset could be the go-to product when anti-PD-1 therapy has failed. The stock closed up 22% yesterday, allowing the group to ...Oct 1, 2021 · Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ... Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 11.71 +0.53 (+4.74%) At close: 04:00PM EST 11.71 0.00 (0.00%) After hours: 04:20PM EST 1d 5d 1m...

Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory …Today's Daily Dose brings you news about AnaptysBio's generalized pustular psoriasis trial results, Cyclerion discontinuing its Sickle Cell Disease drug program, FDA approving the first drug for Ebola, analyst's new price target of Replimune stock, and Vertex halting its phase II study of VX-814 in patients with alpha-1 antitrypsin deficiency.Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients. About Us. ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Replimune stock. Possible cause: Not clear replimune stock.

PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …1,703.30 -8.20(-0.48%) Crude Oil 76.65 -0.52(-0.67%) Gold 1,943.70 +6.00(+0.31%) Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. …

WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab.They pay benefits on behalf of the employees. Healthcare and life insurance without premiums. Good benefits, could use HSA. Great benefits, growing company, plenty to learn. Free health care is very good. Good stock options, and retirement matching.

tharimmune See Replimune Group, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... Based on 10 analysts giving stock ratings to REPL in the past 3 months. EPS. …Dec 7, 2022 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. non traded reits listshare price lloyds bank 15 Okt 2020 ... Replimune stock rallied on leaked RP1 and RP2 clinical trial data. Its cash position enables it to invest more in clinical studies. where would you invest 100k PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …Stock analysis for Replimune Group Inc (REPL:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. herseys stockqqqm holdingsotcmkts phil Shares of Replimune Group Inc. (REPL) surged more than 46% to touch a new high of $46.28 in intraday trading on Wednesday after an analyst at Roth Capital Tony Butler hiked his price target on the ... c3ai stocks Investors are always looking for stocks that are poised to beat at earnings season and Replimune REPL may be one such company. The firm has earnings coming up pretty soon, and events are shaping ... is spacex going publicbest way to day trade cryptobest portfolio manager Nov 3, 2022 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ... View 13F filing holders of Replimune Group Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. ... *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page*** Elevate your investments Try it for free. We give you the access and tools ...